About Us
Technology & Pipeline
Governance
Investors
Media
Contact

About Us
Technology & Pipeline
Corporate Governance
Investors
Media
Contact

Press releases

All releases

Regulatory Releases
Press Releases

2023

2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
All years

Non Regulatory

January 11, 2023

Vivesto announces Inceptua decision to withdraw market authorization application for Apealea® in Switzerland

Investor contact

[email protected]

+46 18-50 54 40

Subscribe to our news

Media

About Us
Technology & Pipeline
Corporate Governance
Investors
Media
Contact

Vivesto AB is a specialty pharmaceutical company focused on thedevelopment of new therapeutic options for patients suffering from hard-to-treatcancers. It has an emerging pipeline of clinical-stage assets targeting late-stagecancers. Apealea® (paclitaxel micellar) is being made available to ovarian cancerpatients through a partnership with Elevar Therapeutics, Inc. Development programsinclude Cantrixil, in clinical development for late-stage ovarian cancer, and docetaxelmicellar, in development for advanced prostate cancer. Vivesto has proprietary drugdelivery technology designed to improve solubility, efficacy and safety.

The Share

Follow the share

Personal data
Cookies

OAS-MA-P-001-SEP2020

Vivesto AB
Vallongatan 1
SE-752 16 Uppsala

Tel +46 18 50 54 40
Fax +46 18 51 08 73
info@vivesto.com